Online Mutation Report

Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa

J C Booij, R J Florijn, J B ten Brink, W Loves, F Meire, M J van Schooneveld, P TVM de Jong, A A B Bergen

Objective: To identify mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa.

Methods: Mutation analysis was carried out in a group of 35 unrelated patients with juvenile autosomal recessive retinitis pigmentosa (ARRP), Leber’s congenital amaurosis (LCA), or juvenile isolated retinitis pigmentosa (IRP), by denaturing high performance liquid chromatography followed by direct sequencing.

Results: All three groups of patients showed typical combinations of eye signs associated with retinitis pigmentosa: pale optic discs, narrow arterioles, pigmentary changes, and nystagmus. Mutations were found in 34% of patients: in CRB1 (11%), GUCY2D (11%), RPE65 (6%), and RPGRIP1 (6%). Nine mutations are reported, including a new combination of two mutations in CRB1, and new mutations in GUCY2D and RPGRIP1. The new GUCY2D mutation (c.3283delC, p.Pro1069ArgfsX37) is the first pathological sequence change reported in the intracellular C-terminal domain of GUCY2D, and did not lead to the commonly associated LCA, but to a juvenile retinitis pigmentosa phenotype. The polymorphic nature of three previously described (pathological) sequence changes in AIPL1, CRB1, and RPGRIP1 was established. Seven new polymorphic changes, useful for further association studies, were found.

Conclusions: New and previously described sequence changes were detected in retinitis pigmentosa in CRB1, GUCY2D, and RPGRIP1; and in LCA patients in CRB1, GUCY2D, and RPE65. These data, combined with previous reports, suggest that LCA and juvenile ARR are closely related and belong to a continuous spectrum of juvenile retinitis pigmentosa.

Retinitis pigmentosa (RP) denotes a group of hereditary retinal dystrophies with a worldwide prevalence of approximately 1 in 4000. The disease is clinically and genetically very heterogeneous. The phenotype of the juvenile form of RP shows overlap with Leber’s congenital amaurosis (LCA), an autosomal recessive retinal dystrophy with a worldwide prevalence of 1 in 35 000. Patients with juvenile RP are considered to have good central vision during the first decade of life, while the age of onset of severe visual impairment in LCA ranges from birth to the first year of life. Retinitis pigmentosa is characterised by night blindness, progressive constriction of the visual field, pale discs, retinal vascular narrowing, pigmentary changes in the retina, and reduced electroretinogram (ERG) amplitudes. LCA is characterised by congenital nystagmus, a decreased pupillary response, pigmentary changes in the retina (although the fundoscopic appearance is initially normal), and reduced ERG amplitudes. Various intermediate phenotypes between LCA and RP are known and are sometimes described as “early onset severe rod-cone dystrophy” or “early onset retinal degeneration.” The clinical distinction between the subtypes of RP is not always clear, and the diagnostic criteria are frequently not agreed upon between ophthalmologists. In 29% of patients, RP is part of a syndrome, such as Usher’s or Bardet-Biedl’s. Of the non-syndromal RP cases in the Netherlands, 37% is isolated (IRP); of the remainder, the transmission mode is autosomal recessive in 30%, autosomal dominant in 22%, and X linked in 10%. In addition, several unusual inheritance patterns—such as digenic inheritance and uniparental isodisomy, in which a child inherits two copies of a single parental chromosome—have been observed.

The molecular genetic diversity within the different phenotypes of RP is also well documented. At least 17 genes are currently known to be involved in autosomal recessive RP (ARRP), while five additional loci have been identified. So far, mutations can only be identified in approximately 50% of ARRP and LCA patients. Eight LCA genes have been cloned so far: AIPL1, CRB1, CX, GUCY2D, RDH12, RPE65, RPGRIP1, and TULP1. The genetic overlap between ARRP and LCA is illustrated by the fact that all but three of these genes (AIPL1, CX, and RPGRIP1) were previously implicated in ARRP. The molecular genetic diversity within the different phenotypes of RP is also well documented. At least 17 genes are currently known to be involved in autosomal recessive RP (ARRP), while five additional loci have been identified. So far, mutations can only be identified in approximately 50% of ARRP and LCA patients. Eight LCA genes have been cloned so far: AIPL1, CRB1, CX, GUCY2D, RDH12, RPE65, RPGRIP1, and TULP1. The genetic overlap between ARRP and LCA is illustrated by the fact that all but three of these genes (AIPL1, CX, and RPGRIP1) were previously implicated in ARRP (CRB1, GUCY2D, RDH12, RPE65, RPGRIP1, TULP1).

To illustrate the diversity and complexity of genotype–phenotype correlations in RP and LCA, two examples are mentioned here. Previously, a correlation was suggested between mutations in the RPE65 gene and a phenotype consisting of severe visual impairment within the first year of life, with a measurable visual acuity at the age of six to 10 years, and congenital nystagmus in three of four patients. However, no such correlation was observed in another study. Similarly, two parents diagnosed with RP had a daughter who carried a homozygous RPE65 mutation and who was reported to have LCA (absent or severely diminished vision within the first year of life).

In summary, there appears to be significant overlap between juvenile ARRP and LCA in both a clinical and a genetic sense. This makes the clinical distinction between juvenile ARRP and LCA difficult if not impossible. We hypothesised that mutations in the five most common LCA genes could also be responsible for juvenile ARRP.
Table 1 Characteristics of cloned genes implicated in recessive Leber’s congenital amaurosis according to published reports

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosome location</th>
<th>Described in</th>
<th>Found in (%) of patients</th>
<th>Reference*</th>
<th>Primer reference†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AIPL1</strong></td>
<td>17p13.2</td>
<td>LCA</td>
<td>5–10</td>
<td>13</td>
<td>This study</td>
</tr>
<tr>
<td><strong>CRB1</strong></td>
<td>1q31.3</td>
<td>LCA, ARRP</td>
<td>9–13</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td><strong>CRX</strong></td>
<td>19q13.32</td>
<td>LCA</td>
<td>1–3</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td><strong>GUCY2D</strong></td>
<td>17p13.1</td>
<td>LCA, ARRP</td>
<td>10–20</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td><strong>RDH12</strong></td>
<td>14q24.1</td>
<td>LCA, ARRP</td>
<td>4</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td><strong>RPE65</strong></td>
<td>1q31.2</td>
<td>LCA, ARRP</td>
<td>6–16</td>
<td>18</td>
<td>4</td>
</tr>
<tr>
<td><strong>RPGRII</strong></td>
<td>14q11.2</td>
<td>LCA</td>
<td>4–6</td>
<td>19</td>
<td>31</td>
</tr>
<tr>
<td><strong>TULP1</strong></td>
<td>6p21.31</td>
<td>LCA, ARRP</td>
<td>Several families</td>
<td>20, 21</td>
<td></td>
</tr>
</tbody>
</table>

*References first describing the cloning of the respective genes.
†References describing the primers we used.

ARRP, autosomal recessive RP; IRP, isolated RP; LCA, Leber’s congenital amaurosis.

METHODS

Patients

This study was performed in agreement with the declaration of Helsinki. Patients included in the study or their legal representatives gave permission for blood to be drawn for mutation detection. All patients diagnosed with ARRP and IRP with a disease onset before age 20 years, as well as all patients with an LCA diagnosis, and presenting to the Netherlands Ophthalmic Research Institute (NORI) were included in the study. Most patients were Dutch, four were Belgian, one originated from Turkey, one had a Mexican and a Dutch parent, and one had an Indonesian and a Dutch parent.

The diagnoses of RP and LCA were based on a combination of the following criteria.

For RP, the criteria were: (subjective) night blindness, a pale optic disc, narrow arterioles, pigmentary changes, ERG amplitude reduction (>50%), and visual field abnormalities, compatible with RP. Patients were considered to have juvenile RP when their first reported symptoms occurred before the age of 20.

For LCA, the criteria were: signs of blindness or severe visual impairment from birth or within the first year of life, an ERG reduction of more than 50%, and congenital nystagmus.1

Patients were diagnosed with autosomal recessive inheritance when they had two unaffected parents and one or more affected siblings or consanguineous parents. Patients were diagnosed with IRP when no affected relatives were known, and there was no parental consanguinity, or no inheritance pattern could be established. Patients were excluded when their family tree showed evidence of autosomal dominant or X linked inheritance, or when their RP or LCA was part of a syndrome.

Mutation detection

The DNA isolated from peripheral blood was stored at 4°C until use.20 The following primers were used for the amplification of **AIPL1**: exon 1 forward (1F) cttggtcccctgtcttccttt, exon 1 reverse (1R) ggctttgagctgctggg, 2F ggctctgcaacgttgtctca, 2R gacgccggagagaagcag, 3F gccctttgtatgcccacacta, 3R cttgctctctgctgtcgctg, 4F tgtggctctgcctgtcatcaga, 4R ccacaga gtcagcgccactt, 5F aagtgctcgcctgcctggg, 5R tgtgctctgcctgtcgccgctg, 6F cctctggaaggctgggaaggga, 6R gacccagccactggctcctc. Primers used for **CRB1**, **GUCY2D**, **RPE65**, and **RPGRII** along with their characteristics are referred to in table 1.

The length of the polymerase chain reaction (PCR) product was checked on a 2% agarose gel, after which it was mixed with an equal volume of PCR product from a healthy control person in order to detect homozygous sequence changes. This was followed by a heteroduplex formation step before samples were analysed for mutations using denaturing high performance liquid chromatography analysis (DHPLC) (Transgenicen, Santa Clara, California, USA) at two or three different temperatures.

Exons showing a DHPLC pattern that differed from a healthy control, and the healthy control itself, were reamplified and purified using a QIA-quick PCR purification kit (Qiagen, Valencia, California, USA) for direct sequencing. A sequence reaction (25 cycles consisting of 10 seconds at 96°C, five seconds at 50°C, and four minutes at 60°C) was carried out using forward and reverse primers separately (table 1). Sequence products were precipitated with 75% isopropanol and dissolved in template suppression reagent, after which the products were denatured at 94°C for two minutes. Samples were subsequently analysed using the ABI-310 (Applied Biosystems, Foster City, California, USA). We described mutations using the following Genbank reference cDNA sequences22: **AIPL1**, gi67676706; **CRB1**, NM_012076.2; **GUCY2D**, NM_000180.1; **RPGRII**, NM_020366.2; **RPE65**, gi3077820; the first A of the ATG was chosen as nucleotide +1, and the ATG as codon +1.33

Definition of pathogenicity

We considered a sequence variation to be pathogenic when we found it exclusively in patients and not in at least 120 chromosomes from 60 control persons. In addition, we made a literature based prediction of the effect of a new mutation, using the description of mutations in or the function of similar domains. We considered sequence variations polymorphic when their allele frequency was not significantly higher in patients than in control persons, or when they did not co-segregate with the disease phenotype in a family. Our patient group consisted of 35 patients and our control group of at least 60 healthy persons (120 chromosomes).

RESULTS

Patients

Our mutation screening panel consisted of 17 ARRP, nine LCA, and nine IRP patients. Table 2 shows the clinical characteristics of the 12 patients in whom we found mutations.

Visual field changes corresponding to RP were seen in ARRP, IRP, and LCA patients. As expected, an ERG reduction of at least 50% was reported in nearly all RP and LCA patients (data were missing for two patients). Nystagmus, corresponding to an LCA phenotype, was seen in all LCA patients and in one IRP patient. The RP and LCA patients, in whom no mutations were found, showed similar overlapping clinical features (data not shown).
Table 2  Clinical characteristics of patients with juvenile autosomal recessive retinitis pigmentosa, Leber’s congenital amaurosis, and juvenile isolated retinitis pigmentosa in whom mutations were identified in the present study

<table>
<thead>
<tr>
<th>Patient</th>
<th>Diagnosis</th>
<th>Age at last examination</th>
<th>Age of onset</th>
<th>Pale optic disc</th>
<th>Narrow arterioles</th>
<th>Pigment changes</th>
<th>ERG reduction &gt;50%</th>
<th>Visual field</th>
<th>Nystagmus</th>
</tr>
</thead>
<tbody>
<tr>
<td>8432</td>
<td>ARRP</td>
<td>67</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25378</td>
<td>ARRP</td>
<td>14</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25855</td>
<td>ARRP</td>
<td>67</td>
<td>20</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>9359</td>
<td>LCA</td>
<td>30</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>22802</td>
<td>LCA</td>
<td>43</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>24670</td>
<td>LCA</td>
<td>35</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>26649</td>
<td>LCA</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25140</td>
<td>IRP</td>
<td>15</td>
<td>1.5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25474</td>
<td>IRP</td>
<td>32</td>
<td>20</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25718</td>
<td>IRP</td>
<td>24</td>
<td>14</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>26425</td>
<td>IRP</td>
<td>9</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Age in years or months (m).
†Pigmentary changes could be present either peripherally or throughout the entire retina, and could have the appearance of either typical bone spicules or non-specific pigmentary abnormalities.

ARRP, autosomal recessive retinitis pigmentosa; IRP, isolated retinitis pigmentosa; LCA, Leber’s congenital amaurosis.

Table 3  Mutations in patients with juvenile autosomal recessive retinitis pigmentosa, Leber’s congenital amaurosis, and juvenile isolated retinitis pigmentosa

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequence variation (official name)</th>
<th>Predicted effect (official name)</th>
<th>Predicted effect (traditional name)</th>
<th>Patient</th>
<th>Disease</th>
<th>Reference†</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRB1</td>
<td>[c.2536A&gt;T][c.2978G&gt;A]</td>
<td>[p.Lys801X][p.Cys948Tyr]</td>
<td>Lys801X and Cys948Tyr</td>
<td>25378</td>
<td>ARRP</td>
<td>14, 22, this study†</td>
</tr>
<tr>
<td></td>
<td>[c.2978G&gt;A]</td>
<td>[p.Cys948Tyr]</td>
<td>Cys948Tyr</td>
<td>22802</td>
<td>LCA</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>[c.2978G&gt;A]</td>
<td>[p.Cys948Tyr]</td>
<td>Cys948Tyr</td>
<td>26649</td>
<td>IRP</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>[c.2978G&gt;A]</td>
<td>[p.Cys948Tyr]</td>
<td>Cys948Tyr</td>
<td>25140</td>
<td>IRP</td>
<td>14</td>
</tr>
<tr>
<td>GUCY2D</td>
<td>[c.3283delC]</td>
<td>[p.Pro1069ArgfsX37]</td>
<td>Pro1069Arg</td>
<td>25556</td>
<td>IRP</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>[c.2176C&gt;T]</td>
<td>[p.Pro701Ser]</td>
<td>Pro701Ser</td>
<td>25855</td>
<td>ARRP</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>[c.2176C&gt;T]</td>
<td>[p.Pro701Ser]</td>
<td>Pro701Ser</td>
<td>8432</td>
<td>ARRP</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>[c.2379T&gt;C]</td>
<td>[p.Arg768Trp]</td>
<td>Arg768Trp</td>
<td>26649</td>
<td>IRP</td>
<td>40</td>
</tr>
<tr>
<td>RPE65</td>
<td>[c.1102T&gt;C][c.1115G&gt;A]</td>
<td>[p.Tyr368His][splice site]</td>
<td>Tyr368His</td>
<td>24670</td>
<td>LCA</td>
<td>36, 40</td>
</tr>
<tr>
<td></td>
<td>[c.1102T&gt;C][c.1102T&gt;C]</td>
<td>[p.Tyr368His]</td>
<td>Tyr368His</td>
<td>9359</td>
<td>LCA</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>[c.3341A&gt;G]</td>
<td>[p.Asp1114Glu]</td>
<td>Asp1114Glu</td>
<td>25140</td>
<td>IRP</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>[c.3341A&gt;G]</td>
<td>[p.Asp1114Glu]</td>
<td>Asp1114Glu</td>
<td>25474</td>
<td>IRP</td>
<td>31</td>
</tr>
</tbody>
</table>

*Traditional name of RPE65:c.115G→A is RPE65:IVS1+5G→A.
†First published description of the mutation.

This combination of mutations has not been described in any published report.

ARRP, autosomal recessive retinitis pigmentosa; IRP, isolated retinitis pigmentosa; LCA, Leber’s congenital amaurosis.
Table 4  Frequency of known and new polymorphisms in patients with juvenile autosomal recessive retinitis pigmentosa, Leber’s congenital amaurosis, and juvenile isolated retinitis pigmentosa in this study

<table>
<thead>
<tr>
<th>Gene</th>
<th>Exon/intron</th>
<th>Sequence variation (official name)</th>
<th>Sequence variation (traditional name)</th>
<th>Predicted effect (official name)</th>
<th>Allele frequency in patients (%)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIPL1</td>
<td>ex 3</td>
<td>c.286G→A</td>
<td>286G→A</td>
<td>p.Val96Ile</td>
<td>1.3</td>
<td>13, this study*</td>
</tr>
<tr>
<td></td>
<td>IVS3</td>
<td>283-35T→C</td>
<td>IVS3-35C→T</td>
<td></td>
<td>2.6</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>IVS4</td>
<td>c.330-34C→T</td>
<td>IVS4-34C→T</td>
<td></td>
<td>5.3</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c.330-34C→A</td>
<td>IVS4-34C→A</td>
<td></td>
<td>2.6</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>ex 2</td>
<td>c.614T→C</td>
<td>614T→C</td>
<td>p.Ile205Thr</td>
<td>1.3</td>
<td>44, this study*</td>
</tr>
<tr>
<td></td>
<td>IVS1</td>
<td>c.24-12A→T</td>
<td>IVS1-12A→T</td>
<td></td>
<td>7.9</td>
<td>44</td>
</tr>
<tr>
<td>GUCY2D</td>
<td>ex 3</td>
<td>c.814C→T</td>
<td>814C→T</td>
<td></td>
<td>19.7</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>ex 9</td>
<td>c.2011C→T</td>
<td>2011C→T</td>
<td></td>
<td>1.3</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>ex 2</td>
<td>c.134T→C</td>
<td>134T→C</td>
<td>p.Trp21Arg</td>
<td>10.5</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>ex 10</td>
<td>c.2182G→A</td>
<td>2182G→A</td>
<td>p.Ala703Ala</td>
<td>15.8</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>ex 12</td>
<td>c.2419C→A</td>
<td>2419C→A</td>
<td>p.Leu782His</td>
<td>15.8</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>ex 20</td>
<td>c.3528C→T</td>
<td>3528C→T</td>
<td></td>
<td>39.5</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>IVS13</td>
<td>c.859-37G→T</td>
<td>IVS13-37G→T</td>
<td></td>
<td>14.5</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>ex 10</td>
<td>c.1056G→A</td>
<td>1056G→A</td>
<td></td>
<td>7.9</td>
<td>4</td>
</tr>
<tr>
<td>RPE65</td>
<td>ex 10</td>
<td>c.446-20A→C</td>
<td>IVS12-20A→C</td>
<td></td>
<td>3.9</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>IVS12</td>
<td>c.446-20A→C</td>
<td>IVS12-20A→C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPGRIP1</td>
<td>IVS6</td>
<td>c.302-16.15insATA</td>
<td>IVS6-16.15insATA</td>
<td></td>
<td>6.6</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>IVS6</td>
<td>c.907-153.154delGG</td>
<td>IVS6-153.154delGG</td>
<td></td>
<td>10.5</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>ex 4</td>
<td>c.525A→G</td>
<td>525A→G</td>
<td>p.Pro175Pro</td>
<td>5.3</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>ex 4</td>
<td>c.574A→G</td>
<td>574A→G</td>
<td>p.Lys192Glu</td>
<td>9.2</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>ex 13</td>
<td>c.1639G→T</td>
<td>1639G→T</td>
<td>p.Ala547Ser</td>
<td>14.5</td>
<td>19, 45, this study*</td>
</tr>
<tr>
<td></td>
<td>ex 14</td>
<td>c.1797G→A</td>
<td>1797G→A</td>
<td>p.Pro599His</td>
<td>18.4</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>ex 15</td>
<td>c.2292G→A</td>
<td>2292G→A</td>
<td>p.Ala764Asp</td>
<td>2.6</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>ex 18</td>
<td>c.3097G→C</td>
<td>3097G→C</td>
<td>p.Gln1033Glu</td>
<td>23.7</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>ex 22</td>
<td>c.3546C→T</td>
<td>3546C→T</td>
<td>p.Asp1182Asp</td>
<td>6.6</td>
<td>19</td>
</tr>
</tbody>
</table>

Polymorphisms described in bold have either not been reported before or have been described as disease causing missense mutations (*)
Mutations
We identified nine different mutations in 12 patients (34%), in the CRB1 (11%), GUCY2D (11%), RPE65 (6%), and RPGRIP1 (6%) genes. In three of these patients two mutations were found (9%)—one patient had a homozygous mutation and two had a compound heterozygous mutation. In nine patients we detected a mutation in a single allele only. We found a mutation in three ARRP patients (17%), in four LCA patients (44%), and in five IRP patients (56%). Two of the mutations identified in this study are new, and we describe a new combination of two mutations. All mutations are presented in table 3.

The first new mutation identified in this study was a heterozygous deletion resulting in a frameshift in GUCY2D:c.3283delC, p.Pro1069ArgfsX37 in IRP patient 25556. This male patient had a disease onset at age 1.5 years. At age 13 he had a visual acuity of 0.1, a severely reduced ERG, a limited visual field, and nystagmus. Co-segregation of the deletion in the family could not be determined owing to the unavailability of parental DNA. However, the deletion was not found in our control population. We also identified GUCY2D mutations in ARRP patients 25855 and 8432 (p.Pro701Ser) and in LCA patient 26669 (p.Arg768Trp).13

The second new mutation was a deletion causing a frameshift in RPGRIP1:c.1614_1623del, p.Glu538Glufs2 in IRP patient 25140. Visual problems in this patient were noted in the second year of life; she had a visual acuity of 0.1 at the age of 15, and experienced night blindness and colour vision impairment. Fundoscopy revealed an atrophic macular area, and the ERG was severely reduced. We did not detect this deletion in our control population. In addition, we found one known RPGRIP1 mutation in IRP patient 25474 (p.Asp1114Gly).14

We found a new combination of two mutations in CRB1 in ARRP patient 25378 ([c.2536A→T, p.Cys948Tyr]+[c.2978G→A, p.Lys801X])15. The age of onset was five years; at age 14, the visual acuity was finger counting, and subjective night blindness was reported. Earlier data on visual acuity and night blindness were missing. The ERG was severely reduced and the fundoscopic picture showed narrowed arterioles, a pale optic disc, and pigmentary changes in the periphery. CRB1 mutations were also found in LCA patient 22802 and in IRP patients 25718 and 26425 (p.Cys948Tyr).14

In the RPE65 gene we found mutations in LCA patient 9359 ([p.Tyr368His]+[c.11G→A])16 17 and in LCA patient 24670 (p.Tyr368His homozgyously). We confirm the pathogenic nature of the RPE65 c.11G→A sequence change. It is located in a donor splice site where the G nucleotide is predicted to be conserved in 84% of primate splice sites.18 19 20 In addition, we do not find it in our controls.15

Polymorphic sequence changes
We observed seven new and 15 known polymorphisms in all five genes. In addition, we established or confirmed the polymorphic nature of three sequence changes previously described as pathogenic mutations. Table 4 summarises the polymorphisms along with their allele frequency in our patient population.

We identified seven new polymorphic sequence changes which are described below. Three new intronic polymorphisms were located in the CRB1 gene (c.283-35T→C, c.330+34C→T, and c.330-54C→A), and two new silent polymorphisms were found in GUCY2D (c.814C→T, p.His247His and c.2011C→T, p.Leu646Leu). In RPGRIP1 a new insertion (c.302-16, -15insATA), and a new deletion (c.907-153, -154delGG) was found. Bioinformatic analysis of all intronic sequence changes did not lead to changes in the splice sites. Analysis of the silent polymorphisms did not reveal predicted changes in exonic splicing enhancers.41 42

We identified three sequence changes of uncertain pathogenic nature. In published reports, these are tentatively described as polymorphisms. The first sequence change was A1PL1:c.286G→A, p.Val96Ile,22 with an allele frequency in patients of 1%, and in matched control persons of 7% (n = 122 chromosomes). The second sequence change, CRB1:c.6147T→C, p.Ile205Thr,23 was found only once in our patient population (allele frequency 1%). We did not find it in our controls. However, we found no co-segregation with the disease phenotype in ARRP family 21724 (fig 1). The third sequence change we identified was RPGRIP1:c.1639G→T, p.Ala547Ser24 with similar allele frequencies of 14% in patients and 13% in controls. Interestingly, in three patients with that Ala547Ser variation, we detected an additional heterozygous pathogenic mutation: (GUCY2D:p.Pro701Ser (ARRP patient 25855), RPGRIP1:p.Asp1114Gly (IRP patient 25474). IRP patient 25140, as well as her unaffected father, had the RPGRIP1:p.Ala547Ser variation in combination with the RPGRIP1:p.Glu538Glufs2 mutation. The latter indicates that the p.Ala547Ser sequence change in combination with the p.Glu538Glufs2 mutation is not sufficient to lead to an RP phenotype.

DISCUSSION
Both clinically and genetically, there was a considerable overlap between our RP patients and our LCA patients. Clinically, visual field changes, as seen in RP, were present in RP patients and in two LCA patients. Nystagmus, which is frequently seen in LCA, was observed in LCA patients as well as in an IRP patient. In addition, fundoscopic changes were seen in ARRP, IRP, and LCA patients. In summary, CRB1 and GUCY2D mutations were found in RP patients as well as in LCA patients, RPE65 mutations were found only in LCA patients, and RPGRIP1 mutations, previously only described in LCA, were newly identified in two RP patients.

Mutations: frequency and distribution
In this study we found nine mutations in 34% of our 35 patients. We identified mutations in 56% of our LCA patients, which corresponds well to published reports (50%),28 29 although in contrast to the current study, most other studies did not screen for all known RP genes at once. In 27% of our ARRP patients we found one or two mutations, which is less than previously reported.12 This may reflect the fact that we screened our patients for LCA gene mutations, and not for all the known RP gene mutations. Screening our ARRP patients for additional known RP gene mutations will most probably lead to the detection of several more mutations.

In spite of the recessive nature of the disease, a second disease causing mutation was not found in nine of 12 patients. The design of our DHPLC analysis (sensitivity close to 99%) makes it unlikely that a second exonic mutation in one of the screened genes was left undetected.11 12 Obviously, it remains possible that promoter or regulatory sequences of the screened genes contain as yet unidentified mutations. The spectrum of mutations in our study (CRB1 (11%), GUCY2D (11%), RPE65 (6%), and RPGRIP1 (6%)) shows only slight differences compared to those reported in the literature. This indicates that the gene distribution in our cohort is similar to juvenile RP and LCA populations worldwide.13 14 16 19 18

New mutations
Two new mutations were identified in this study. The first is the first the mutation reported in the intracellular C-terminal domain of GUCY2D:c.3283delC, p.Pro1069ArgfsX37, in IRP
nystagmus indicate a phenotypic overlap with LCA.

field changes compatible with an RP phenotype. However, this IRP patient. Patient 25556 had an age of onset and visual

disturb this process, leading to an RP phenotype, as seen in

domains,16 34 except for the intracellular C-terminal domain.

changes. Patient VI:1, with retinitis pigmentosa with PPRPE (preservation of the para-arteriolar retinal pigment epithelium, or RP12), had two mutations

cilium.51 RPGR plays a role in the maintenance of photo-
cilia of human cone and rod photoreceptors that connect

unstable, mRNA or a dysfunctional protein.

patient 25556. The deletion creates a stop codon at position

1106 of the cDNA, which results in a larger, most likely

unstable, mRNA or a dysfunctional protein. GUCY2D is a well

conserved protein, containing an extracellular ANF receptor
domain, a transmembrane domain, an intracellular protein

kinase homology domain, and an intracellular guanylate
cyclase domain.49 Mutations have been described in all these
domains,16 34 except for the intracellular C-terminal domain.

The function of the latter domain is unknown. GUCY2D is one of the enzymes indirectly responsible for the regulation of

phototransduction in the photoreceptor cells through regulation

of cGMP levels.50 An altered GUCY2D protein could disturb this process, leading to an RP phenotype, as seen in

this IRP patient. Patient 25556 had an age of onset and visual

field changes compatible with an RP phenotype. However, the

lack of fundoscopy changes and the presence of

nystagmus indicate a phenotypic overlap with LCA.

The second new mutation identified in this study is

RPGRIP1:c.1614_1623del, p.Glu538Glufs2 in IRP patient

25140. A stop codon is introduced at position 540 of the

cDNA, which will prevent the transcription of the protein

kinase C conserved region 2 (C2) and the

RPGR binding domain.51 The RPGRIP1 protein is localised in the connecting

cilia of human cone and rod photoreceptors that connect

inner and outer segments, where it binds RPGR to the
cilium.52 RPGR plays a role in the maintenance of photo-

receptor viability.53 RPGR mutations were previously found in

X linked RP, and RPGRIP1 mutations are known to cause

LCA.19 31 Therefore we consider this RPGRIP1 deletion likely
to be involved in RP, even though a second mutation was not

found in this patient (25140). Patient 25140 had a constricted

visual field, a visual acuity at age 15 of 0.1, and no

nystagmus, which goes against the diagnosis of LCA.

However, the absence of fundoscopic changes, the relatively

eye onset (1.5 years), and the presence of colour vision

defects are more typical of an LCA related phenotype.

This patient is a typical example of the phenotypic overlap

that exists between juvenile RP and LCA.7

Polyorphic sequence changes

We established or confirmed the polyorphic nature of three

sequence changes previously reported as pathogenic muta-
tions. The first (AIPL1:c.286G→A, p.Val96Ile) was previously
described as a disease causing mutation.42 We consider it to

be a rare neutral polyomorphic change because of its high

allele frequency (7%) in our control subjects. The second

sequence change we report to be polyorphic

(RPGRIP1:c.6147T→C, p.Ile205Thr) was initially described as a
disease causing mutation in a Spanish ARRIP family.54 More

recently it was reported in a Dutch study as a polyomorphic

sequence change.15 We find it heterozygously in a single

family where it does not co-segregate with the disease

phenotype (fig 1). Moreover, the change is absent in 192

control chromosomes, which lead us to suggest that

Ile205Thr is a rare neutral sequence change. Unless

we expect that eventually more clarity will come from

molecular genetic analysis of the underlying gene defects.
REFERENCES


49 Website (http://www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl?name = Q02846).


51 Hong DH, Yue G, Adamian M, Li T. Retinitis pigmentosa GTPase regulator (RPGR)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium. J Biol Chem 2001;276:12091–9.


Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa

J C Booij, R J Florijn, J B ten Brink, W Loves, F Meire, M J van Schooneveld, P TVM de Jong and A A B Bergen

doi: 10.1136/jmg.2005.035121

Updated information and services can be found at:
http://jmg.bmj.com/content/42/11/e67

These include:

References

This article cites 45 articles, 14 of which you can access for free at:
http://jmg.bmj.com/content/42/11/e67#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Eye Diseases (298)
Hereditary eye disease (92)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/